Integer Holdings Corporation (ITGR) 주식 분석

회사 개요

Integer Holdings Corporation operates as a specialized medical device contract development and manufacturing entity serving clients across the United States, Costa Rica, Puerto Rico, Ireland, and international markets. The company focuses on providing products for interventional cardiology, structural heart applications, heart failure management, peripheral vascular care, and neurology solutions. It functions within the Healthcare sector, specifically targeting the Medical Devices industry, a space characterized by high regulatory standards and significant capital requirements for product innovation. With a market capitalization of $3.04B and annual revenue reaching $1.85B, the firm demonstrates a substantial presence in the global supply chain for medical technologies. The employee base of 11,000 individuals underscores the scale of operations required to maintain complex manufacturing facilities and support a diverse portfolio of medical solutions. These valuation and revenue figures indicate that the company holds a significant position in the contract manufacturing landscape, leveraging its extensive operational footprint to serve a broad range of medical device manufacturers. The breadth of its geographic reach and the diversity of its product categories suggest a robust business model designed to mitigate risks associated with reliance on a single therapeutic area or region.

재무 건전성

The company reported revenue of $1.85B over the trailing twelve months, with net income of $102.83M and EBITDA of $377.19M. The substantial gap between the $1.85B revenue and the $102.83M net income highlights a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a significant portion of top-line growth. Free cash flow stands at $76.88M, which indicates the company generates sufficient cash from operations to cover capital expenditures and maintain financial flexibility for strategic initiatives. Gross margin is recorded at 27.4%, reflecting the pricing power and manufacturing efficiency inherent in the contract development and manufacturing model. Operating margin sits at 12.8%, showing the profitability after covering direct operating costs, while the profit margin of 5.5% illustrates the final net return relative to total sales. The company holds $17.16M in cash against total debt of $1.32B, resulting in a debt-to-equity ratio of 75.44, which suggests a leveraged balance sheet typical for capital-intensive manufacturing firms. Despite the high debt load, the current ratio of 3.32 indicates strong short-term liquidity, as current assets significantly exceed current liabilities. Return on equity is 6.1% and return on assets is 4.7%, revealing that management effectiveness in generating returns on the capital base is moderate given the industry's competitive nature.

밸류에이션 평가

The trailing twelve-month P/E ratio is 29.99, while the forward P/E is 12.00, implying a significant expectation of future earnings acceleration relative to current performance. The price-to-book ratio of 1.70 suggests the market values the company at a premium of 70% over its book value, reflecting intangible assets or growth prospects not fully captured on the balance sheet. Price-to-sales is 1.64 and EV/EBITDA is 11.35, providing alternative valuation perspectives that weigh revenue quality and cash generation efficiency against market price. The stock's 52-week high was $127.56 and the low was $62.00, indicating a wide trading range that reflects market sentiment volatility over the past year. The beta of 0.71 shows that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings compared to large-cap equities. This combination of a high forward P/E and low beta presents a valuation profile that investors must weigh against the company's current earnings trajectory and debt obligations. The divergence between trailing and forward P/E ratios is particularly notable and requires careful analysis of upcoming earnings reports to validate the growth assumptions embedded in the forward multiple.

Growth & Income

Revenue growth is 5.0% year-over-year, while earnings growth is 52.9% year-over-year, indicating that earnings are expanding significantly faster than revenue. This disparity suggests that the company is benefiting from operational leverage, cost efficiencies, or margin expansion as volume increases. As a non-dividend payer, the company does not distribute a dividend yield, and the payout ratio is 0.0%, meaning all earnings are retained within the business. This reinvestment strategy allows the company to fund research and development, expand manufacturing capacity, or reduce debt without relying on external capital markets for growth funding. The overall growth and income profile is characterized by rapid earnings expansion driven by underlying business growth rather than shareholder distributions. Investors analyzing the growth potential should focus on the sustainability of the 52.9% earnings growth rate and whether it can be maintained as revenue growth normalizes to the 5.0% level. The absence of dividends aligns with a growth-oriented capital allocation policy common in the medical device manufacturing sector where capital reinvestment is prioritized over immediate income generation.